Chrysotoxine Attenuates Key Atherogenic Processes via Antioxidant, Anti-Inflammatory, and COX-Dependent Antiplatelet...

Area of Science:

• Biochemistry
• Pharmacology
• Vascular Biology

Background:

• Atherosclerosis is a vascular disease driven by oxidative stress, inflammation, and platelet activation.
• Multi-target agents may offer superior therapeutic benefits for atherosclerosis.
• Chrysotoxine is a bibenzyl compound from *Dendrobium pulchellum*.

Purpose of the Study:

• To evaluate the anti-atherogenic effects of chrysotoxine.
• To investigate chrysotoxine's impact on LDL oxidation, endothelial inflammation, and platelet aggregation.
• To explore the molecular mechanisms of chrysotoxine's action.

Main Methods:

• In vitro models of atherogenesis, including LDL oxidation assays and endothelial-monocyte co-cultures.
• Assessment of chrysotoxine's effect on lipopolysaccharide-induced monocyte adhesion.
• Evaluation of chrysotoxine's inhibition of platelet aggregation induced by various agonists.
• Molecular docking and cyclooxygenase (COX) activity assays.

Main Results:

• Chrysotoxine suppressed hemin-induced LDL oxidation by reducing lipid peroxidation and apolipoprotein modification.
• Chrysotoxine attenuated lipopolysaccharide-induced monocyte adhesion, inhibiting endothelial inflammation.
• Chrysotoxine inhibited platelet aggregation, particularly against arachidonic acid-induced responses, suggesting thromboxane pathway modulation.
• Chrysotoxine exhibited inhibitory activity against COX-1 and COX-2 in the low micromolar range.

Conclusions:

• Chrysotoxine effectively modulates key atherogenic processes: oxidative LDL modification, vascular inflammation, and platelet activation.
• Chrysotoxine demonstrates multi-target potential for treating atherosclerosis.
• Further in vivo studies are warranted to confirm chrysotoxine's therapeutic efficacy.